This work bridges the gap between dental science and stem cell and tissue engineering
Part 1: Developmental Biology: A Blueprint for Tissue
Engineering
Part 2: In Vitro Regulation of Cell Behaviour and Tissue
Development
Part 3: Biomaterials in Tissue Engineering
Part 4: Oral and Craniofacial Stem Cells for Tissue Engineering
Part 5: Tooth Tissue Engineering
Part 6: Tissue Engineering in Endodontics
Part 7: Periodontal Tissue Engineering
Part 8: Craniofacial Tissue Engineering
Part 9: Bioengineering Organs in Head and Neck
Part 10: Tissue Engineering Skin and Oral Mucosa
Part 11: Tissue Engineered Implant Dentistry
Part 12: Tissue Engineering in Orthodontics & Dentofacial
Orthopedics
Part 13: Transplantation of Engineered Tissue Constructs
Part 14: Research Ethics and Law
Dr Ajay Vishwakarma is a researcher in the fields of stem cell
bio-engineering, biomaterials, tissue engineering, cancer
immunology and immuno-engineering; working with Division of
Engineering in Medicine, Department of Medicine, at Brigham and
Women’s Hospital, Harvard Medical School and an affiliate at the
Harvard-MIT Division of Health Sciences and Technology at the
Massachusetts Institute of Technology.
Dr Vishwakarma earned a Doctors degree in Dental Surgery at
Maharashtra University of Health Sciences and Masters degree in
Tissue Engineering at Cardiff University, UK where he primarily
studied signaling pathways involved in musculoskeletal repair and
regeneration. He continued mesenchymal stem cell and
tissue-engineering research during his fellowship in the
Khademhosseini laboratory at the Harvard-MIT Division of Health
Sciences and Technology, USA. Currently he is pursuing a PhD in
Cancer Biology with training in Cancer Immunology at the Carver
College of Medicine, University of Iowa in Prof. Weizhou Zhang’s
Laboratory, Department of Pathology, Holden Cancer Center wherein
he is studying how regulatory T cells impact cancer progression and
metastasis in humanized cancer models.
He was a recipient of a stem cell training fellowship from CCMB, a
CSIR Indian institute, a graduate research fellowship by National
Blood Foundation and National Cancer Institute government grant
agencies. In addition to the long-term academic interest; he is
committed to translating next generation cell-based therapies and
has held key industrial positions in Europe and Asia. He is a
co-founder of OCTE Technologies, a biotech start-up utilizing cell
and tissue engineering technology platform to solve medical
problems. Professor Paul Sharpe is the Dickinson Professor of
Craniofacial Biology at Kings College London. He graduated with a
degree in biology from York University (1977) and a PhD in
biochemistry from Sheffield University (1981). Following postdocs
in Sheffield, Wisconsin and Cambridge he became lecturer in
molecular embryology at the University of Manchester in 1987 where
he established a research group working on the molecular control of
tooth development. Following promotion to Reader in 1991 he was
recruited to his present Chair at the Dental Institute of Guy’s
Hospital (later to merge with Kings College), where he established
a new basic research department, the Department of Craniofacial
Development and Stem Cell Biology. The department, of which he
remains head, now consists of 13 academic research groups with over
80 research staff. From 2002-2008 he was Director of Research for
the Dental Institute. His main research interests are the molecular
control of tooth development, dental stem cell biology and tooth
bioengineering. He has published over 270 research papers including
articles in Nature, Science, PNAS and Cell press. He has supervised
over 40 PhD students and receives funding from the MRC. He is a
member of the MRC Centre for Transplantation and Biomedical
Research Centre. In 2004 he was awarded the Craniofacial Biology
Research Award by the International Association for Dental Research
in recognition of his contribution to the understanding of how
teeth develop and in 2006 his paper “Stem cell-based tissue
engineering of teeth received the William J Gies award for best
publication is Biomaterials and Bioengineering from the same
organisation. He is on the editorial boards of several journals
including J. Dent. Res. and J. Clin. Perio. Songtao Shi, D.D.S.,
Ph.D., is Professor at the University of Southern California Ostrow
School of Dentistry. Dr. Shi received his D.D.S. degree and
certificate in Pediatric Dentistry from the Peking University
School of Stomatology and Ph.D. in Craniofacial Biology from the
University of Southern California. Prior to joining the faculty at
the University of Southern California, he served as a Principal
Investigator and Clinical Fellow for nine years at the National
Institute of Dental and Craniofacial Research. His research program
focuses on understanding mechanism of mesenchymal stem cell
(MSC)-associated diseases, developing new experimental disease
models, and exploring feasibility of translating these bench
discoveries to clinical therapies.
His group and his collaborators were the first to identify dental
pulp stem cells, baby tooth stem cells, periodontal ligament stem
cells, root apical papilla stem cells, tendon stem cells, gingiva
stem cells, sclera MSCs, and benign tumor MSCs from keloid and
ossifying fibroma. In translational study, Dr. Shi’s team has used
these stem cells to regenerate a variety of tissues, including
dentin, pulp, periodontal ligament, tendon, bone, bio-root. Dr. Shi
and his collaborators were the first to use MSCs to treat systemic
lupus erythematosus (SLE), periodontitis, bisphosphonate-related
osteonecrosis of the jaw-like disease (BRONJ) in animal models and
patients. Additionally, Dr. Shi and his collaborators were the
first to generate BRONJ, osteoradionecrosis, keloid, and ossifying
fibroma diseases in mouse and swine models. To understand
mechanisms of MSC-based therapies, Dr. Shi’s team revealed that MSC
mediated bone regeneration was regulated by recipient T cell, which
is the pioneer study showing association between cell-based tissue
engineering and immune response. Additionally, Dr. Shi and his
collaborators discovered that MSC-mediated immunotherapy in human
and mouse model is associated the interplay between the donor cells
and recipient T cells via Fas/FasL pathway. Recently, Dr. Shi’s
team first time showed that MSCs contribute to orofacial benign
tumor development via an epigenetic regulation network.
Dr. Shi has published more than 150 peer-reviewed articles in a
variety of high-impact scientific journals, of which he served as
the corresponding author in Nat Medicine, Cell Stem Cell, Lancet, J
Clin Invest, Nat Biotechnol, Proc Natl Acad Sci U S A, Cell
Research, Blood, J Bone Miner Res, Stem Cells, PLoS ONE, and J Dent
Res. Dr. Shi’s research is supported by NIH grants and funding from
California Institute of Regenerative Medicine.
Dr. Shi has served on several local and national committees and
boards including Scientific Editor for the PLoS ONE and Associate
Editor for Oral Diseases. He is recipient of the 2013 IADR
Distinguished Scientist Award for Pulp Biology & Regeneration. He
is on the editorial board of Stem Cell Research & Therapy, the
editorial board of World Journal of Stem Cells, and the editorial
board of Chinese Journal of Dental Research. Dr. Shi is Changjing
Scholar in the Fourth Military Medical University, Distinguished
Visiting Professor in Tongji University, Visiting Professor in
XiangYa School of Medicine & Stomatology, Central South University
(CSU), and distinguished visiting professor in Dankook University,
Korea.
Murugan Ramalingam, PhD, FNS, FIoN, FRSC is Professor at the Centre
for Stem Cell Research (a unit of the Institute for Stem Cell
Biology and Regenerative Medicine-Bengaluru), Christian Medical
College Campus, India. Concurrently he is Adjunct Professor at the
Tohoku University, Japan. Prior to joining the CSCR, he worked as
Associate Professor of Biomaterials and Tissue Engineering at the
Institut National de la Santé et de la Recherche Médicale, Faculté
de Chirurgie Dentaire, Université de Strasbourg (France) and at the
WPI Advanced Institute for Materials Research (Japan) as Assistant
Professor. He has also worked at the National Institute of
Standards and Technology (NIST) and the National Institutes of
Health (NIH), under the U.S. National Academies Associateship
program. He received his Ph.D. in Biomaterials from the University
of Madras. He has also undergone training in Ethical and Policy
issues on Stem Cells from Harvard University (USA), and in
Operations Management from the University of Illinois-Chicago
(USA). His current research interests are focused on the
development of multiphase biomedical materials, through
conventional to nanotechnology to biomimetic approaches,
microfabrication, cell patterning, stem cell differentiation,
tissue engineering and drug delivery. He is the author of over 275
publications, including peer-reviewed journal papers, conference
proceedings, book chapters, authored books, edited books, and
patents relevant to biomaterials, stem cells, and tissue
engineering. His current h-index is 30 with ~6500 citations. He
also serves as a board member of several international scientific
and research committees in various public and private bodies and
grant reviewer of various international funding agencies. He serves
on the editorial boards of multiple biomaterials, stem cells and
tissue engineering-related journals, including as the
Editor-in-Chief of the Journal of Biomaterials and Tissue
Engineering, the Journal of Bionanoscience and the Stem Cell
Research and Therapy. He is a recipient of several prestigious
fellowships and awards, including CSIR Fellowship (India), SMF
Fellowship (Singapore), NRC National Academies Fellowship (USA),
Nationale Professeur des Universités (France), Fellow of Institute
of Nanotechnology (UK) and Fellow of Royal Society of Chemistry
(UK).
Ask a Question About this Product More... |